申请人:Pfizer Inc.
公开号:US06649636B1
公开(公告)日:2003-11-18
This invention relates to a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is (C1-C4)alkyl optionally substituted with halo, amino or an alkyl amino; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
本发明涉及以下公式的化合物或其药学上可接受的盐,其中A和R1分别为可选取代的5至6元杂环芳基,其中杂环芳基可选择与碳环或5至6杂环芳基融合;R2为(C1-C4)烷基,可选择取代卤素,氨基或烷基氨基;R3和R4分别为氢,卤素,可选择取代卤素等的(C1-C4)烷基;X1至X4分别为氢,卤素,羟基,可选择取代卤素等的(C1-C4)烷基。这些化合物具有COX-2抑制活性,因此可用于治疗或预防炎症或其他与COX-2相关的疾病。